SCHEMBL5728618

SCHEMBL5728618

O=C1Nc2ccccc2C1=Cc1c[nH]nc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.63
RPS6KA3 P51812 2/20 0.60
ALK Q9UM73 2/20 0.60
PLK1 P53350 2/20 0.58
NPC1 O15118 3/20 0.53
PLK4 O00444 1/20 0.53
GSK3B P49841 3/20 0.52
CSNK1A1 P48729 3/20 0.52
NTRK1 P04629 2/20 0.52
DAPK3 O43293 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
ABL1 P00519 1/20 0.52
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
CSF1R P07333 1/20 0.52
RET P07949 1/20 0.52
PDGFRB P09619 1/20 0.52
PDGFRA P16234 1/20 0.52
LTK P29376 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5728617 1.00 FLT3 (0.63) FLT3RPS6KA3ALKPLK1NPC1
SCHEMBL6630620 0.80 FLT3 (0.40) FLT3RPS6KA3ALKPLK1NPC1
SCHEMBL6630626 0.80 FLT3 (0.40) FLT3RPS6KA3ALKPLK1NPC1
SCHEMBL6630629 0.80 FLT3 (0.40) FLT3RPS6KA3ALKPLK1NPC1
SCHEMBL3285276 0.77 FLT3 (1.00) FLT3RPS6KA3ALKPLK1NPC1
SCHEMBL3284018 0.77 FLT3 (1.00) FLT3RPS6KA3ALKPLK1NPC1
SCHEMBL3284013 0.77 FLT3 (1.00) FLT3RPS6KA3ALKPLK1NPC1
SCHEMBL6625374 0.74 PLK1 (0.36) FLT3RPS6KA3ALKPLK1PLK4
SCHEMBL6625378 0.74 PLK1 (0.36) FLT3RPS6KA3ALKPLK1PLK4
SCHEMBL6625369 0.74 PLK1 (0.36) FLT3RPS6KA3ALKPLK1PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680401-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER Schering Aktiengesellschaft (DE) 2006-07-19 EP claimed
WO-2005040116-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER SCHERING AKTIENGESELLSCHAFT (DE) 2005-05-06 WO claimed
US-20050090541-A1 Indolinone derivatives and their use in treating disease-states such as cancer SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-28 US claimed
US-7105563-B2 Indolinone derivatives and their use in treating disease-states such as cancer SCHERING AKTIENGESELLSCHAFT (DE) 2006-09-12 US disclosed
EP-1680401-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER Schering Aktiengesellschaft (DE) 2006-07-19 EP disclosed
WO-2005040116-A2 INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER SCHERING AKTIENGESELLSCHAFT (DE) 2005-05-06 WO disclosed
US-20050090541-A1 Indolinone derivatives and their use in treating disease-states such as cancer SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090541-A1 Indolinone derivatives and their use in treating disease-states such as cancer PDK3, PDK2, PDK4 FLT3 1806/4885RPS6KA3 262/4885ALK 2359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.